Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases

Derives de l'acide barbiturique utilises comme inhibiteurs de l'enzyme de conversion du tnf-alpha (tace) et/ou de metalloproteases matricielles

Abstract

The present application describes novel barbituric acid derivatives of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R1, R2, R3, R4, R5, n, W, U, X, Y, Z, Ua, Xa, Ya, and Za are defined in the present specification, which are useful as TNF-a converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.
La présente invention concerne de nouveaux dérivés de l'acide barbiturique de la formule (I), ou des sels pharmaceutiquement acceptables ou promédicaments desdits dérivés. Dans ladite formule, A, B, L, R1, R2, R3, R4, R5, n, W, U, X, Y, Z, Ua, Xa, Ya et Za sont tels que définis dans le mémorandum descriptif. Ces dérivés sont utiles comme inhibiteurs de l'enzyme de conversion du TNF-alpha (TACE) et/ou de métalloprotéases matricielles (MMP).

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (2)

    Publication numberPublication dateAssigneeTitle
    US-2002132822-A1September 19, 2002Noe Mark C., Reiter Lawrence A., Wythes Martin J.Pyrimidine-2,4,6-trione metalloproteinase inhibitors
    US-6242455-B1June 05, 2001Roche Diagnostics GmbhPyrimidin-2,4,6-trion derivatives, method for producing the same and medicinal products containing these compounds

NO-Patent Citations (0)

    Title

Cited By (34)

    Publication numberPublication dateAssigneeTitle
    CN-105814045-AJuly 27, 2016Ucb生物制药私人有限公司作为tnf活性调节剂的咪唑并吡啶衍生物
    EP-2105164-A1September 30, 2009Affectis Pharmaceuticals AGNeuartige P2X7R-Antagonisten und ihre Verwendung
    EP-2181704-A2May 05, 2010Angiotech International AgDrug delivery from rapid gelling polymer composition
    JP-2012503664-AFebruary 09, 2012ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツングCcr1受容体拮抗薬としてのアザインダゾール化合物
    US-7504401-B2March 17, 2009Locus Pharmaceuticals, Inc.Anti-cancer agents and uses thereof
    US-7645881-B2January 12, 2010Ptc Therapeutics, Inc.Methods for treating hepatitis C
    US-7683085-B2March 23, 2010Schering CorporationCompounds for the treatment of inflammatory disorders
    US-7683088-B2March 23, 2010Schering CorporationCompounds for the treatment of inflammatory disorders
    US-7687527-B2March 30, 2010Schering CorporationCompounds for the treatment of inflammatory disorders
    US-7772263-B2August 10, 2010Schering CorporationCompounds for the treatment of inflammatory disorders
    US-7772271-B2August 10, 2010Ptc Therapeutics, Inc.Methods for treating hepatitis C
    US-7781478-B2August 24, 2010Ptc Therapeutics, Inc.Methods for treating hepatitis C
    US-7868037-B2January 11, 2011Ptc Therapeutics, Inc.Methods for treating hepatitis C
    US-7879890-B2February 01, 2011Schering CorporationCompounds for the treatment of inflammatory disorders
    US-7973069-B2July 05, 2011Ptc Therapeutics, Inc.Methods for treating hepatitis C
    US-7977477-B2July 12, 2011Astex Therapeutics, LimitedBenzimidazole derivatives and their use as protein kinase inhibitors
    US-8013006-B2September 06, 2011Ptc Therapeutics, Inc.Methods for treating hepatitis C
    US-8110573-B2February 07, 2012Astex Therapeutics LimitedPyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
    US-8178553-B2May 15, 2012Schering CorporationCompounds for the treatment of inflammatory disorders
    US-8383827-B2February 26, 2013Novartis AgAryl pyridine as aldosterone synthase inhibitors
    US-8399442-B2March 19, 2013Astex Therapeutics LimitedPharmaceutical compounds
    US-8435970-B2May 07, 2013Astex Therapeutics LimitedPharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
    US-8450355-B2May 28, 2013Merck Sharp & Dohme Corp.Compounds for the treatment of inflammatory diseases
    US-8541572-B2September 24, 2013Merck Sharp & Dohme Corp.Compounds for the treatment of inflammatory disorders
    US-8778936-B2July 15, 2014Astex Therapeutics LimitedPyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
    US-8809545-B2August 19, 2014Novartis AgAryl pyridine as aldosterone synthase inhibitors
    US-8859529-B2October 14, 2014Merck Sharp & Dohme Corp.Compounds for the treatment of inflammatory disorders
    WO-2010118921-A1October 21, 2010Affectis Pharmaceuticals AgNouveaux antagonistes de p2x7r et leur utilisation
    WO-2012110190-A1August 23, 2012Affectis Pharmaceuticals AgNovel p2x7r antagonists and their use
    WO-2012163456-A1December 06, 2012Affectis Pharmaceuticals AgNovel p2x7r antagonists and their use
    WO-2012163792-A1December 06, 2012Affectis Pharmaceuticals AgNouveaux antagonistes de p2x7r et leur utilisation
    WO-2015086507-A1June 18, 2015Ucb Biopharma SprlDérivés d'imidazopyridine comme modulateurs de l'activité du tnf